Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.
For the induction of mucosal immune responses by intranasal vaccination, cholera toxin B subunits (CTB) and Escherichia coli heat-labile toxin (LT) are often administered as mucosal adjuvants in order to enhance immune responses to mucosally co-administered bystander antigens. However, these toxin also are the causative agents of diarrhea. There is a demand for the establishment of an effective and safer adjuvant or vaccine that elicits mucosal immunity, but does not require the use of CTB or LT adjuvants. In order to induce protective mucosal immune responses in the nasal area against influenza virus infection, we have examined the recombinant protein composed of the complement component, C3d, which is fused to the secreted form of hemagglutinin (sHA-mC3d3) in the influenza-BALB/c mouse model. The fusion protein sHA-mC3d3, the secretory form of hemagglutinin, and the transmembrane form of HA (tmHA) from the influenza virus were intranasally administered to the mice with or without CTB containing a trace amount of holotoxin (CTB*) as an adjuvant. After intranasal administration of these proteins with CTB*, all mice produced nasal IgA and serum IgG antibodies (Abs) against the viral HA. In addition, viral infection was completely inhibited in these mice. In contrast, in the absence of the adjuvant, only sHA-mC3d3-induced locally secreted IgA and serum IgG Abs and provided complete protection against the influenza virus challenge. Thus, C3d fused to the influenza HA antigen is an effective and safe tool for mucosal vaccination.
Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjyuku-ku, Tokyo 162-8640, Japan.
Izumi
I
Watanabe
Ted M
TM
Ross
Shin-ichi
S
Tamura
Takeshi
T
Ichinohe
Satoshi
S
Ito
Hidehiro
H
Takahashi
Hirofumi
H
Sawa
Joe
J
Chiba
Takeshi
T
Kurata
Tetsutaro
T
Sata
Hideki
H
Hasegawa
D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D002460:Cell Line; D005260:Female; D005434:Flow Cytometry; D006388:Hemagglutinins / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology; D007070:Immunoglobulin A / Q000096:biosynthesis; D007202:Indicators and Reagents; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009975:Orthomyxoviridae / Q000276:immunology; D010957:Plasmids / Q000235:genetics / Q000276:immunology; D017464:Receptors, Complement 3d / Q000008:administration & dosage / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology / Q000302:isolation & purification; D014760:Viral Fusion Proteins / Q000276:immunology
D000276:Adjuvants, Immunologic; D006388:Hemagglutinins; D007070:Immunoglobulin A; D007202:Indicators and Reagents; D017464:Receptors, Complement 3d; D011994:Recombinant Proteins; D014760:Viral Fusion Proteins